United States-based Sen-Jam Pharmaceuticals and United States-based development and manufacturing company KVK Tech, announced on Thursday that they are collaborating to develop a Covid-19 oral therapy.
Both firms are to operate in parallel while they complete the Phase II clinical trials in Nepal. KVK Tech is to provide formulation and chemistry, manufacturing and controls (CMC) for the oral therapy. KVK is also investing strategically in Sen-Jam to conclude the whole development activities required to provide the CMC package to the Food and Drug Administration (FDA) for submitting a new drug application (NDA).
Under the partnership, KVK will have exclusive manufacturing and supply rights for the product in the US, while Sen-Jam is to use the finished formulation and CMC report to enter licensing deals with contracting manufacturing companies (CMOs) globally.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval